These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6802548)

  • 1. Ethosuximide plasma concentrations: influence of age and associated concomitant therapy.
    Battino D; Cusi C; Franceschetti S; Moise A; Spina S; Avanzini G
    Clin Pharmacokinet; 1982; 7(2):176-80. PubMed ID: 6802548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.
    Battino D; Estienne M; Avanzini G
    Clin Pharmacokinet; 1995 Oct; 29(4):257-86. PubMed ID: 8549027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproic acid and ethosuximide interaction.
    Mattson RH; Cramer JA
    Ann Neurol; 1980 Jun; 7(6):583-4. PubMed ID: 6776874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethosuximide in the treatment of absence (peptit mal) seizures.
    Browne TR; Dreifuss FE; Dyken PR; Goode DJ; Penry JK; Porter RJ; White BG; White PT
    Neurology; 1975 Jun; 25(6):515-24. PubMed ID: 805382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
    Glauser TA; Cnaan A; Shinnar S; Hirtz DG; Dlugos D; Masur D; Clark PO; Capparelli EV; Adamson PC;
    N Engl J Med; 2010 Mar; 362(9):790-9. PubMed ID: 20200383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved control of epilepsy by monitoring plasma ethosuximide.
    Sherwin AL; Robb JP; Lechter M
    Arch Neurol; 1973 Mar; 28(3):178-81. PubMed ID: 4631034
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors influencing plasma concentrations of ethosuximide.
    Smith GA; McKauge L; Dubetz D; Tyrer JH; Eadie MJ
    Clin Pharmacokinet; 1979; 4(1):38-52. PubMed ID: 421410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of tolerance to the anticonvulsant effect of valproate but not to ethosuximide in a rat model of absence epilepsy.
    Wahle H; Frey HH
    Eur J Pharmacol; 1990 May; 181(1-2):1-8. PubMed ID: 2117539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproate-ethosuximide combination therapy for refractory absence seizures.
    Rowan AJ; Meijer JW; de Beer-Pawlikowski N; van der Geest P; Meinardi H
    Arch Neurol; 1983 Dec; 40(13):797-802. PubMed ID: 6416232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of treatment in typical absence seizures. The roles of long-term EEG monitoring and ethosuximide.
    Blomquist HK; Zetterlund B
    Acta Paediatr Scand; 1985 May; 74(3):409-15. PubMed ID: 3923777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethosuximide dosage regimens.
    Buchanan RA; Kinkel AW; Turner JL; Heffelfinger JC
    Clin Pharmacol Ther; 1976 Feb; 19(2):143-7. PubMed ID: 816588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children.
    Ueshima S; Aiba T; Makita T; Nishihara S; Kitamura Y; Kurosaki Y; Kawasaki H; Sendo T; Ohtsuka Y; Gomita Y
    J Clin Pharm Ther; 2008 Feb; 33(1):31-8. PubMed ID: 18211614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of primidone and its metabolite phenobarbital: effect of age and associated therapy.
    Battino D; Avanzini G; Bossi L; Croci D; Cusi C; Gomeni C; Moise A
    Ther Drug Monit; 1983; 5(1):73-9. PubMed ID: 6845402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma levels of anticonvulsants. Experiences with routine plasma level determination of 6 different anticonvulsants].
    Klotz U
    Fortschr Med; 1978 Jan; 96(1):9-13. PubMed ID: 340366
    [No Abstract]   [Full Text] [Related]  

  • 15. Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy.
    Capovilla G; Beccaria F; Veggiotti P; Rubboli G; Meletti S; Tassinari CA
    J Child Neurol; 1999 Jun; 14(6):395-400. PubMed ID: 10385848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is ethosuximide a risk factor for generalised tonic-clonic seizures in absence epilepsy?
    Schmitt B; Kovacevic-Preradovic T; Critelli H; Molinari L
    Neuropediatrics; 2007 Apr; 38(2):83-7. PubMed ID: 17712736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness of ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
    Hwang H; Kim H; Kim SH; Kim SH; Lim BC; Chae JH; Choi JE; Kim KJ; Hwang YS
    Brain Dev; 2012 May; 34(5):344-8. PubMed ID: 21893390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of uridine diphosphate glucuronosyltransferase inducers and inhibitors on the plasma lamotrigine concentration in pediatric patients with refractory epilepsy.
    Yamamoto Y; Takahashi Y; Imai K; Ikeda H; Takahashi M; Nakai M; Inoue Y; Kagawa Y
    Drug Metab Pharmacokinet; 2015 Jun; 30(3):214-20. PubMed ID: 25825021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Blood level of antiepileptic drugs and therapeutic effect in mono- and polytherapy (author's transl)].
    Deisenhammer E; Sommer R
    Nervenarzt; 1978 Nov; 49(11):674-7. PubMed ID: 103010
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical pharmacokinetics of anticonvulsants.
    Hvidberg EF; Dam M
    Clin Pharmacokinet; 1976; 1(3):161-88. PubMed ID: 797496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.